Phase I/II study shows improved progression-free survival in advanced lung cancer patients, indicating potential benefits of lymphocyte-targeting therapy.
Supplementary Figure 1. Kaplan-Meier estimation of progression-free survival in (A) squamous non-small cell lung cancer (NSCLC), (B) adenocarcinoma NSCLC, overall survival in (C) squamous NSCLC and (D) adenocarcinoma NSCLC.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: